A novel de novo mutation of β-cardiac myosin heavy chain gene found in a twelve-year-old boy with hypertrophic cardiomyopathy

Journal of Genetics

Volumn 93, Issue 2, 2014, Pages 557-560

  Okada, Seigo ^a   Suzuki, Yasuo ^a   Arimura, Takuro ^b   Kimura, Akinori ^b   Narumi, Hiroko ^a   Hasegawa, Shunji ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

de novo; HCM; MYH7; pediatrics; point mutation

Indexed keywords

CARDIAC MYOSIN; MYH7 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN;

CARDIOMYOPATHY, HYPERTROPHIC; CASE REPORT; CHILD; GENETIC ASSOCIATION; GENETICS; HUMAN; MALE; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE;

BASE SEQUENCE; CARDIAC MYOSINS; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; DNA MUTATIONAL ANALYSIS; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MUTATION, MISSENSE; MYOSIN HEAVY CHAINS;

EID: 84910595277     PISSN: 00221333     EISSN: 09737731     Source Type: Journal    
DOI: 10.1007/s12041-014-0414-8     Document Type: Article

References (20)

1. Choi J. O., Yu C. W., Nah J. C., Park R. J., Lee B. S., Choi J. Y., et al. 2010 Long-term outcome of 4 Korean families with hypertrophic cardiomyopathy caused by 4 different mutations. Clin. Cardiol.33, 430–438.
2. Fananapazir L. and Epstein N. D. 1994 Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation89, 22–32.
3. Franz W. M., Muller O. J., and Katus H. A. 2001 Cardiomyopathies: From genetics to the prospect of treatment. Lancet358, 1627–1637.
4. García-Castro M., Coto E., Reguero J. R., Berrazueta J. R., Alvarez V., Alonso B., et al. 2009 Mutations in sarcomeric genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in patients with hypertrophic cardiomyopathy. Rev. Esp. Cardiol.62, 48–56.
5. Ho C. Y. and Seidman C. E. 2006 A contemporary approach to hypertrophic cardiomyopathy. Circulation113, e858–862.
6. Kimura A. 2010 Molecular basis of hereditary cardiomyopathy: abnormalities in calcium sensitivity, stretch response, stress response and beyond. J. Hum. Genet.55, 81–90.
7. Kubo T., Kitaoka H., Okawa M., Baba Y., Hirota T., Hayato K., et al. 2011 Genetic screening and double mutation in Japanese patients with hypertrophic cardiomyopathy. Circ. J.75, 2654– 2659.
8. Maron B. J. 2002 Hypertrophic cardiomyopathy: A systematic review. JAMA287, 1308–1320.
9. Maron B. J., Cecchi F., and McKenna W. J. 1994 Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br. Heart J.72, 13–18.
10. Maron B. J., Estes N. A. 3rd., Maron M. S., Almquist A. K., Link M. S., and Udelson J. E. 2003 Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation107, 2872–2875.
11. Maron B. J., Maron M. S., and Semsarian C. 2012 Genetics of hypertrophic cardiomyopathy after 20 years: Clinical perspectives. J. Am. Coll. Cardiol.60, 705–715.
12. Melacini P., Maron B. J., Bobbo F., Basso C., Tokajuk B., Zucchetto M., et al. 2007 Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart93, 708–710.
13. Otsuka H., Arimura T., Abe T., Kawai H., Aizawa Y., Kubo T., et al. 2012 Prevalence and distribution of sarcomeric gene mutationsin Japanese patients with familial hypertrophic cardiomyopathy. Circ. J.76, 453–461.
14. Richard P., Charron P., Carrier L., Ledeuil C., Cheav T., Pichereau C., et al. 2003 Hypertrophic cardiomyopathy: Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation107, 2227–2232.
15. Towbin J. A. 2000 Molecular genetics of hypertrophic cardiomyopathy. Curr. Cardiol. Rep.2, 134–140.
16. Towbin J. A. and Bowles N. E. 2002 The failing heart. Nature415, 227–233.
17. Van Driest S. L., Jaeger M. A., Ommen S. R., Will M. L., Gersh B. J., Tajik A. J., et al. 2004 Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.44, 602–610.
18. Van Driest S. L., Ommen S. R., Tajik A. J., Gersh B. J., and Ackerman M. J. 2005 Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin. Proc.80, 463–469.
19. Wang S., Zou Y., Fu C., Xu X., Wang J., Song L., et al. 2008 Worse prognosis with gene mutations of beta-myosin heavy chain than myosin-binding protein C in Chinese patients with hypertrophic cardiomyopathy. Clin. Cardiol.31, 114–118.
20. Watkins H., Rosenzweig A., Hwang D. S., Levi T., McKenna W., Seidman C. E., et al. 1992 Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. New Engl. J. Med.326, 1108–1114.